XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.70

-0.8%

Jan 23 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert S. who wrote (9068)	3/10/1999 9:46:00 AM
From: aknahow	Read Replies (1) of 17367

Robert_S, thanks. best information on DSMB I have seen to date. At the risk of taking part of it out of context I was struck by this: "Based on these comprehensive analyses, the DSMB may recommend termination of the trial. In general, some of the considerations which enter into that decision are whether the accumulated data provide compelling, conclusive results with respect to the principal outcomes in an intention-to-treat analysis. Here this is not purely a matter of statistical significance for any one outcome. Rather, it is a matter of whether all of the objectives of the trial have been met, or alternately whether no further gains are expected to accrue if the trial were to continue to its originally designed conclusion." Given the supposedly FDA mandated target mortality, it would seem difficult for any DSMB to recommend termination before that, "objective of the trial", had been met. Other parts also seem to support this. I have a bias, and may be seeing only what I want to see.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next